Skip to content

Stem Cell Based Products in Europe and in China: Where are We and Where Should we Go?

Vera Lúcia Raposo, Li Du


Stem cell based products are considered cutting-edge technology in the medical field and form the basis of advanced forms of medicine, namely regenerative medicine. Although Europe (within the framework of the European Union) and China have invested immense amounts of capital in these new technologies, both have become targets of criticism. In particular, concerns have been raised regarding clinical trials, human subject protection and patient/consumer safety. This paper argues that these issues are related to the existence of laws that are out of tune with the demands of science and technology, a complex multiplicity of regulations and an emphasis on innovation and profit, leading to a lack of concern for safety. Given the decisive incorporation of stem cell products into modern medicine, both the European Union and China must address the related legal drawbacks and learn from each other’s mistakes and successes.

Vera Lúcia Raposo is Associate Professor at the Faculty of Law of Macau University, China and Auxiliary Professor at the Faculty of Law of Coimbra University, Portugal. For Correspondence: <>. Li Du is Assistant Professor, Faculty of Law, University of Macau, China. For Correspondence: <>


Lx-Number Search

(e.g. A | 000123 | 01)

Export Citation